Tahoe Therapeutics

Based in California, US, Tahoe Therapeutics operates as a biotechnology company that focuses on developing drugs and treatments using AI and in vivo data. The company was founded by Nima Alidoust (CEO), Johnny Yu (CSO), Hani Goodarzi, and Kevan Shokat. In December 2022, Vevo Therapeutics, Inc. raised USD 12 million in seed funding led by General Catalyst Partners and Wing, AIX Ventures, Camford Capital, and Mubadala Capital.

In August 2025, Tahoe Therapeutics raised USD 30 million in venture funding led by new investor Amplify Partners, with participation from other new investors Civilization Ventures, Conviction, Databricks Ventures, and Overlap Holdings. Returning investors AIX Ventures, General Catalyst Partners, Mubadala Capital, Wings Capital Ventures, and other unspecified investors also participated in the round. The company offers a platform to generate high-resolution in vivo data at scale. The single-cell resolution offered by the firm measures both phenotypic and transcriptomic changes in cell states and captures general rules of drug efficacy.

The firm can also determine drug action across all patients in one experiment in one tumor and single-cell RNA profiling. The platform studies drug-cell interactions in vivo. The company plans to use the funding to study how different drugs affect human cells so scientists can find better ways to treat diseases.